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Susceptibility profiles of medically important fungi in
less-developed countries remain uncharacterized. We
measured the MICs of amphotericin B, 5-flucytosine, flu-
conazole, itraconazole, and ketoconazole for Cryptococcus
neoformans clinical isolates from Thailand, Malawi, and the
United States and found no evidence of resistance or MIC
profile differences among the countries.
P
rompt identification of agents associated with emerg-
ing infectious diseases and documentation of resist-
ance among these agents to available antimicrobial drugs
depend on existing surveillance activities for emerging
pathogens and antimicrobial resistance. Although the
World Health Organization has undertaken initiatives (1)
in these areas, surveillance of antimicrobial resistance in
developing countries is lacking or has been generally
ignored (2). Natural selective pressures exerted on
microorganisms by routine, inappropriate, or excessive use
of antimicrobial drugs are factors in the development of
antimicrobial resistance. In tropical developing countries,
unrestricted availability of antimicrobial drugs without
prescriptions, suboptimal therapeutic regimens, blind
empiric prescribing practices that are not epidemiological-
ly directed, and lack of laboratory capacity or skilled per-
sonnel for susceptibility testing contribute to the spread of
antimicrobial resistance (2). Although numerous studies
have examined bacterial and mycobacterial resistance in
the tropics, less is known about the susceptibility profiles
of medically important fungi to antifungal agents (3–5).
Given that only a few antimicrobial drugs may be available
in developing countries because of limited resources or
cost restrictions, the surveillance for resistance among
common pathogens to available drug treatment is essential
for appropriate patient care and improved patient outcome. 
Cryptococcus neoformans, an opportunistic fungal
pathogen that causes disease predominantly in immuno-
compromised patients, is a frequent cause of fatal mycotic
infections among patients with AIDS (6). In sub-Saharan
Africa, cryptococcal meningitis occurs in 30% of AIDS
patients and is likely to remain a substantial cause of death
in these patients unless highly active antiretroviral therapy
becomes available (6–8). Until such a time, treatment with
antifungal agents, including long-term, suppressive anti-
fungal regimens, remains the only recourse. 
The Study
We sought to determine if substantial differences in
susceptibility profiles to common antifungal agents exist-
ed among clinical isolates of C. neoformans from three
geographically diverse areas. Sixty-five clinical isolates of
C. neoformans from Malawi, Thailand, and the United
States were available for study. The 16 isolates from
Malawi and 29 isolates from Thailand were recovered
from the bloodstream of febrile, adult inpatients during
previous bloodstream infection studies in these regions
(9,10). The 20 isolates from the United States were recov-
ered from the bloodstream, lung tissue, cerebrospinal fluid,
and other sterile sites in routine clinical practice in the clin-
ical microbiology laboratories of the Cleveland Clinic
Foundation and Duke University Medical Center. The
yeast isolates from all of the countries were shipped to
Duke University Medical Center for testing and main-
tained in frozen stock vials at –70°C. Sixty-five yeast iso-
lates were recovered from the frozen stock vials on potato
dextrose agar and incubated at 30°C for 48 hours. The anti-
fungal susceptibilities of the isolates were determined by
using the Sensititre YeastOne system (Trek Diagnostic
Systems Ltd., West Sussex, England), which includes
amphotericin B, 5-flucytosine, fluconazole, itraconazole,
and ketoconazole. All isolates were incubated for 72 hours,
according to the manufacturer’s instructions. Inoculum
assessments were performed on all trays and were within
acceptable limits. The trays were visually inspected, and
the MICs were determined according to the manufacturer’s
guidelines. Interpretive guidelines and breakpoints for sus-
ceptibility testing of C. neoformans are not yet available
from the National Committee for Clinical Laboratory
Standards (NCCLS); therefore, only MIC comparisons
were performed (11).
For isolates from each country, we recorded the MIC at
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Florida, USA.which 50% of the isolates were inhibited (MIC50) and the
MIC at which 90% of the isolates were inhibited (MIC90)
and determined the MIC geometric mean for each thera-
peutic agent. We compared the MIC geometric means for
the three countries with a one-way analysis of variance
(ANOVA) to determine if significant differences existed.
Additional comparisons between the MIC50 and MIC90
were not undertaken, since these were within one dilution
of one another. 
The  C. neoformans isolates from the United States,
Thailand, and Malawi demonstrated similar susceptibility
profiles to the common antifungal agents against which
they were tested (Table 1). The percentage of isolates
inhibited at each concentration of antifungal agent over the
full dilution series is summarized in Table 2. The isolates
from the three countries did not differ significantly in their
susceptibility to fluconazole (p = 0.198), itraconazole (p =
0.163), 5-flucytosine (p = 0.713), or ketoconazole (p =
0.531). The geometric mean of the MIC values for ampho-
tericin B in Thailand, the United States, and Malawi was
1.2 µg/mL, 1.4 µg/mL, and 1.6 µg/mL, respectively. These
mean values were significantly (p = 0.019) different.
Conclusions
Resistance to antifungal drugs is rare among clinical
isolates of C. neoformans but has been reported (4,12). The
use of antifungal agents, particularly in long-term suppres-
sive regimens, has raised concern about the development
of drug resistance in C. neoformans. However, an exten-
sive survey of the susceptibility profiles of clinical isolates
of C. neoformans at a university hospital during 1987 to
1994 helped to allay these fears by indicating no emer-
gence of resistance (13). 
This study also demonstrates no evidence of resistance
among clinical isolates of C. neoformans from Thailand,
Malawi, and the United States. For each country, the MIC50
and MIC90 of isolates to commonly used antifungal agents
were within one dilution from each other. In addition, the
MIC ranges were similar. Statistical comparison of the MIC
geometric means confirmed that no significant differences
existed between the three regions for fluconazole, itracona-
zole, 5-flucytosine, or ketoconazole. The only statistically
significant differences were observed for amphotericin B
susceptibilities; however, this difference was believed to be
clinically irrelevant since the MIC geometric means for
amphotericin B were 1– 2 µg/mL, or within one dilution.
Our documentation of the absence of resistance among C.
neoformans isolates from the United States is consistent
with data published by the Centers for Disease Control and
Prevention, which showed in vitro resistance to antifungal
agents to be uncommon and unchanged among C. neofor-
mans isolates from 1992 to 1998 (14). 
The similarity between the MICs of C. neoformans iso-
lates from Malawi and the United States concurs with data
from a previous study of 164 African and 402 North
American clinical isolates of C. neoformans isolates that
were tested and found to be susceptible to fluconazole and
other triazoles, with over 99% inhibited by concentrations
of fluconazole <32 µg/mL (5). The MIC50 and MIC90 in
that study were lower than those in this study, although the
YeastOne trays have been found to agree well with the
NCCLS reference method for itraconazole and the other
azoles (15). Also, the MICs of fluconazole documented in
our study are similar to those previously reported for iso-
lates of C. neoformans from the United Kingdom and
Uganda (3,4); the MICs of 5-flucytosine in our study also
were similar to those previously reported for C. neofor-
mans isolates from Uganda (4). The itraconazole MICs
documented in our study were lower than those reported
for isolates from the United Kingdom, Africa, and the
United States (4,5). The differences between the suscepti-
bility profiles of C. neoformans to itraconazole reported in
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Table 1. Cryptococcus neoformans susceptibility results  
Antifungal agent  MIC range (µg/mL)  MIC50 (µg/mL)  MIC90 (µg/mL)  MIC geometric mean (µg/mL) 
U.S. isolates (N = 20) 
Amphotericin B  1–2  1  2  1.4 
Fluconazole  1–16  8  8  5.1 
Itraconazole  0.016–0.125  0.06  0.125  0.06 
5-Flucytosine  2–8  4  8  5.1 
Ketoconazole  <0.008–0.250  0.06  0.06  0.05 
Thailand isolates (N = 29) 
Amphotericin B  0.5–2  1  2  1.2 
Fluconazole  4–160  8  16  7.7 
Itraconazole  0.030–0.125  0.06  0.06  0.06 
5-Flucytosine  2–8  4  8  4.6 
Ketoconazole  0.030–0.250  0.06  0.125  0.07 
Malawi isolates (N = 16) 
Amphotericin B  1–2  2  2  1.6 
Fluconazole  4–32  8  16  7.6 
Itraconazole  0.030–0.125  0.03  0.125  0.05 
5-Flucytosine  1–16  4  8  4.5 
Ketoconazole  0.016–0.250  0.03  0.25  0.03 our study and those reported previously may be due in part
to the poor solubility of this antimicrobial agent in an
aqueous solution.
Using a standardized testing method, we found no sig-
nificant or clinically meaningful differences between the
antifungal susceptibility profiles of clinical isolates of C.
neoformans from the United States, Thailand, and Malawi.
Although rare strains of C. neoformans with elevated
MICs to some antifungal agents may exist, they were not
detected in this sampling of clinically significant C. neo-
formans isolates and, therefore, do not appear to be promi-
nent in Cleveland, Ohio; Durham, North Carolina;
Bangkok, Thailand; or Lilongwe, Malawi.
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Table 2. Percentage of Cryptococcus neoformans isolates 
susceptible at each MIC dilution  
  % Susceptible 





Amphotericin B        
0.5    3   
1  50  72  31 
2  100  100  100 
Fluconazole        
1  5     
2  30     
4  40  21  25 
8  90  83  87 
16  100  100  94 
32      100 
Itraconazole        
0.016  5     
0.030  15  14  50 
0.060  75  93  87 
0.125  10  100  100 
5-Flucytosine        
1      6 
2  5  7  12 
4  60  72  69 
8  100  100  94 
16      100 
Ketoconazole        
<0.008  5     
0.016  20    12 
0.030  35  14  62 
0.060  90  79  75 
0.125  95  93  81 
0.250  100  100  100 